XTLB (XTL Biopharmaceuticals) Common Stock: $25.14 Mil (As of Dec. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
28 GF Score
Price $2.53
! 4 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Common Stock?

XTL Biopharmaceuticals XTLB +1.61% 28 Common Stock is $25.14 Mil as of Dec. 2025. GuruFocus rates XTLB with a GF Score™ of 28/100. The stock has 4 warning signs investors should review.

XTL Biopharmaceuticals's quarterly common stock stayed the same from Dec. 2024 ($23.14 Mil) to Jun. 2025 ($23.14 Mil) but then increased from Jun. 2025 ($23.14 Mil) to Dec. 2025 ($25.14 Mil).

XTL Biopharmaceuticals's annual common stock increased from Dec. 2023 ($14.12 Mil) to Dec. 2024 ($23.14 Mil) and increased from Dec. 2024 ($23.14 Mil) to Dec. 2025 ($25.14 Mil).

XTL Biopharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Common Stock Chart

XTL Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.12 14.12 14.12 23.14 25.14

XTL Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.12 14.12 23.14 23.14 25.14
XTLB
28GF Score
XTL Biopharmaceuticals Ltd XTLB
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $25.14 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Common Stock of $25.14 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Common Stock too high?
XTL Biopharmaceuticals' current Common Stock is $25.14 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Common Stock compare to VRTX and REGN?
XTL Biopharmaceuticals' Common Stock of $25.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Common Stock is $25.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Common Stock of $25.14 Mil. The current Common Stock is $25.14 Mil. XTL Biopharmaceuticals' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Common Stock is $25.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
28GF Score

Get the complete analysis for XTLB

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.53
Price